
Tesla reports 16pc profit drop to US$1.2bn
Shares of Tesla dipped 0.4 percent in after-hours trading on Wednesday. Photo: Reuters
Tesla reported another drop in quarterly profits on Wednesday on lower auto sales amid intensifying electric vehicle competition and lingering backlash over CEO Elon Musk's involvement in US politics.
The company reported second-quarter profits of US$1.2 billion, down 16 percent from the year-ago level. In a press release, it emphasised ongoing efforts to lead in artificial intelligence and robotics.
Revenues fell 12 percent to US$22.5 billion.
Lower profits had been expected after Tesla earlier this month disclosed a decline in auto deliveries. Its results were also impacted by a fall in average vehicle selling prices and higher operating expenses driven by AI and other research and development projects.
Tesla did not offer an outlook on full-year vehicle production, citing shifting global trade and fiscal policies.
"While we are making prudent investments that will set up both our vehicle and energy businesses for growth, the actual results will depend on a variety of factors, including the broader macroeconomic environment, the rate of acceleration of our autonomy efforts and production ramp at our factories," Tesla said.
The results come on the heels of Tesla's launch last month of a robotaxi service in the Texas capital, Austin, Musk's first fully autonomous offering after pushing back the timeframe many times.
Musk has heavily touted Tesla's autonomous driving programme, as well as the company's "Optimus" humanoid robot, which employs artificial intelligence technology.
But analysts have criticised Tesla's sluggishness in unveiling new autos, while questioning Musk's commitment to an earlier goal of launching a state-of-the-art electric vehicle priced at around US$25,000 to bolster the odds of mass deployment.
In Wednesday's press release, Tesla said, "We continue to expand our vehicle offering, including first builds of a more affordable model in June, with volume production planned for the second half of 2025."
Shares of Tesla dipped 0.4 percent in after-hours trading. (AFP)

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


The Standard
an hour ago
- The Standard
Ukraine says Starlink's global outage hit its military communications
A Starlink satellite internet system is set up, amid Russia's attack on Ukraine, near the frontline town of Pokrovsk in Donetsk region, Ukraine April 10, 2025. REUTERS/Inna Varenytsia/File Photo


The Standard
3 hours ago
- The Standard
Russian Boeing 737 lands safely after turning back with cabin pressure issue, flight data shows
A Boeing 737 MAX 7 aircraft piloted by Federal Aviation Administration (FAA) Chief Steve Dickson lands during an evaluation flight at Boeing Field in Seattle, Washington, U.S. September 30, 2020. REUTERS/Lindsey Wasson


South China Morning Post
4 hours ago
- South China Morning Post
Pfizer, Chinese biotech firm 3SBio complete worldwide licensing deal for cancer drug
First announced in May, the deal will see 3SBio – based in Shenyang, capital of northeastern Liaoning province – receive a US$1.25 billion upfront payment from Pfizer for the exclusive right to sell its cancer drug, SSGJ-707, outside China. Under the terms of their agreement, Pfizer will also pay 3SBio up to US$150 million to solely develop and commercialise SSGJ-707 within the mainland, the two companies said on Thursday. Pfizer also agreed to buy 31.1 million new shares in S3Bio, or a 1.3 per cent equity stake, for HK$785 million, according to a stock exchange filing. The deal at HK$25.2055 per share represents a 17 per cent discount to its market price on Thursday. 3SBio's shares fell 6.41 per cent to HK$28.45 on Friday. The transaction reflected the strong momentum of Chinese biotech firms in the field of drugs research and the increased interest from major foreign pharmaceutical companies to license their intellectual property.